VENCLEXTA Abbvie Pty Ltd
Product name
VENCLEXTA
Sponsor
Accepted date
May-2024
Active ingredients
venetoclax
Proposed indication
For the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Application type
C (new indication)
Publication date
May-2024